cancer

Hypoglycemia secondary to insulinoma masking the onset of type 1 diabetes in an adolescent
Type 1 diabetes and insulinoma can co-occur in pediatric patients and may present with episodes of hypo- and hyperglycemia, significant …
Sriya Subramani, Andrew M Bellizzi, Nick Borcherding, Simon C Kao, Joseph Dillon, James Howe, Andrew W Norris, Michael J Tansey, Catherina T Pinnaro
PDF Cite DOI Pubmed
The GPR171 pathway suppresses T cell activation and limits antitumor immunity
The recently identified G-protein-coupled receptor GPR171 and its ligand BigLEN are thought to regulate food uptake and anxiety. Though …
Yuki Fujiwara, Robert J Torphy, Yi Sun, Emily N Miller, Felix Ho, Nick Borcherding, Tuoqi Wu, Raul M Torres, Weizhou Zhang, Richard D Schulick, Yuwen Zhu
PDF Cite DOI Pubmed
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex
Epithelioid hemangioendothelioma (EHE) is a vascular sarcoma that metastasizes early in its clinical course and lacks an effective …
Nicole Merritt, Keith Garcia, Dushyandi Rajendran, Zhen-Yuan Lin, Xiaomeng Zhang, Katrina A Mitchell, Nick Borcherding, Colleen Fullenkamp, Michael S Chimenti, Anne-Claude Gingras, Kieran F Harvey, Munir R Tanas
PDF Cite DOI Pubmed
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
Regulatory T cells (Tregs) play an important role in maintaining immune homeostasis and, within tumors, their upregulation is common …
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nick Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang
PDF Cite Code DOI Pubmed
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to …
Nick Borcherding, Ajaykumar Vishwakarma, Andrew P. Voigt, Andrew Bellizzi, Jacob Kaplan, Kenneth Nepple, Aliasger K Salem, Russell W Jenkins, Yousef Zakharia, Weizhou Zhang
PDF Cite Code DOI Pubmed
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment …
Yinwen Cheng, Nick Borcherding, Ayomide Ogunsakin, Caitlin D Lemke-Miltner, Katherine N Gibson-Corley, Anand Rajan, Allen B Choi, Wattawan Wongpattaraworakul, Carlos H F Chan, Aliasger K Salem, George J Weiner, Andrean L Simons
PDF Cite DOI Pubmed
AP-2γ Is Required for Maintenance of Multipotent Mammary Stem Cells
Mammary gland ductal morphogenesis depends on the differentiation of mammary stem cells (MaSCs) into basal and luminal lineages. The …
Vivian W Gu, Edward Cho, Dakota T Thompson, Victoria C Cassady, Nick Borcherding, Kelsey E Koch, Vincent T Wu, Allison W Lorenzen, Dana M van der Heide, Jeffrey R White, Mikhail V Kulak, Trevor Williams, Weizhou Zhang, Ronald J Weigel
PDF Cite DOI Pubmed
Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
Recently antibiotic exposure has been associated with worse outcomes in patients undergoing treatment with antibodies directed against …
Umang Swami, Adithya Chennamadhavuni, Nick Borcherding, Aaron D Bossler, Sarah L Mott, Rohan Garje, Yousef Zakharia, Mohammed Milhem
PDF Cite DOI Pubmed
Big Data Analytics and Cancer Biology: Lessons in Taking Science from the Processor to the Patient
Nick Borcherding
PDF Cite
Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors
Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has …
Praveen Vikas, Nick Borcherding, Adithya Chennamadhavuni, Rohan Garje
PDF Cite DOI Pubmed
Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors